ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,535
-0,42%
Bitcoin
59 932,01
-1,10%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) Actualités

LYRA Lyra Therapeutics Inc

5,16
0,43 (9,09%)
30 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lyra Therapeutics Inc LYRA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,43 9,09% 5,16 23:46:23
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,73 4,68 5,20 5,16 4,73
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202422:04GLOBELyra Therapeutics Reports First Quarter 2024 Financial..
26/4/202422:51GLOBELyra Therapeutics Announces Inducement Grants Under Nasdaq..
21/3/202421:01GLOBELyra Therapeutics Reports Fourth Quarter and Full Year 2023..
01/3/202422:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
15/2/202415:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202400:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:34EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:13EDGAR2Form 8-K - Current report
28/12/202312:40EDGAR2Form 8-K - Current report
18/12/202322:16EDGAR2Form 8-K - Current report
16/11/202323:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/11/202323:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:09EDGAR2Form 8-K - Current report
07/11/202322:01GLOBELyra Therapeutics Reports Third Quarter 2023 Financial..
07/11/202313:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
16/10/202313:00GLOBELyra Therapeutics Announces Appointment of Ronan O’Brien as..
12/9/202322:01EDGAR2Form 8-K - Current report
12/9/202313:00GLOBELyra Therapeutics Announces Positive Topline Results from..
06/9/202314:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
01/9/202322:03EDGAR2Form 8-K - Current report
01/9/202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/8/202313:00GLOBELyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I..
25/8/202322:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:03EDGAR2Form 8-K - Current report
08/8/202322:01GLOBELyra Therapeutics Reports Second Quarter 2023 Financial..
14/7/202322:06EDGAR2Form 8-K - Current report
13/7/202313:30GLOBELyra Therapeutics to Present at William Blair Virtual..
13/7/202300:36EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
07/7/202322:44EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/7/202303:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202303:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202322:06EDGAR2Form S-3 - Registration statement under Securities Act of..
02/6/202322:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
02/6/202313:30GLOBELyra Therapeutics to Present at Jefferies Healthcare..
01/6/202313:29GLOBELyra Therapeutics Announces Closing of $50.0 Million Private..
26/5/202313:57GLOBELyra Therapeutics Announces $50.0 Million Private Placement
12/5/202313:00GLOBELyra Therapeutics Reports First Quarter 2023 Financial..
09/5/202322:01GLOBELyra Therapeutics to Present at Bank of America Securities..

Dernières Valeurs Consultées

NASDAQ
LYRA
Lyra Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés